Conatus Pharmaceuticals, a biotech in Phase 2 trials developing treatments for chronic liver disease, raised $66 million by offering 6 million shares (20% more than the 5 million originally planned) at $11, the midpoint of the $10-$12 range. Conatus Pharmaceuticals plans to list on the NASDAQ under the symbol CNAT. Stifel and Piper Jaffray acted as joint bookrunners on the deal.
